Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth...
Thursday, April 26, 2012, 1:59 PM ETCelgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth and better margins. Net earnings actually jumped 57% Y/Y on strong sales of its flagship blood-cancer treatment Revlimid. Separately, the company says it's entered into a strategic partnership with privately held Epizyme to develop personalized therapies for patients with genetically defined cancers.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles